44,197 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 44,197 shares of the company’s stock, valued at approximately $1,588,000.

Several other hedge funds also recently made changes to their positions in DYN. AQR Capital Management LLC grew its stake in shares of Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after buying an additional 352 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares during the period. Amalgamated Bank grew its position in Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares during the period. Finally, Privium Fund Management B.V. grew its position in shares of Dyne Therapeutics by 7.1% during the 3rd quarter. Privium Fund Management B.V. now owns 15,016 shares of the company’s stock valued at $539,000 after acquiring an additional 1,000 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders sold 176,257 shares of company stock worth $6,193,718 in the last three months. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $29.34 on Tuesday. The business has a fifty day moving average price of $32.42 and a 200 day moving average price of $35.26. Dyne Therapeutics, Inc. has a 1-year low of $10.03 and a 1-year high of $47.45. The stock has a market capitalization of $2.99 billion, a P/E ratio of -8.24 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on DYN. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Piper Sandler restated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.